Is there evidence for development of more severe autoimmune toxicities for young patients vs older patients on immune checkpoint inhibitors?

Topics: Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • UCLA • NCI-CCC Breast Tumor Board Question • Breast Cancer, Non-metastatic • Immune Checkpoint Inhibitor

As immune checkpoint inhibitors have expanded into the neoadjuvant breast cancer setting, severe and unexpected autoimmune toxicities may cause delays in therapy. Are young women (30s-40s) more likely to get autoimmune toxicities?

Related Questions